首頁 > 市場調查報告書 > 製藥

藥物開發開發業務受託機關

臨床實驗新藥（IND）CDMO市場規模、佔有率和成長分析：按服務類型、藥物類型、臨床階段、治療領域和地區分類－2026-2033年產業預測

市場調查報告書

商品編碼

2036385

臨床實驗新藥（IND）CDMO市場規模、佔有率和成長分析：按服務類型、藥物類型、臨床階段、治療領域和地區分類－2026-2033年產業預測

Investigational New Drug CDMO Market Size, Share, and Growth Analysis, By Service Type (API Development & Manufacturing, Formulation Development), By Drug Type, By Phase, By Therapeutic Area, By Region - Industry Forecast 2026-2033

出版日期: 2026年05月07日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球臨床實驗藥物 CDMO 市值為 42.2 億美元，預計到 2033 年將從 2025 年的 47.6 億美元成長至 125.8 億美元，在預測期（2026-2033 年）內複合年成長率為 12.84%。

全球臨床實驗藥物（IND）合約開發和生產組織（CDMO）市場的主要驅動力是生物製藥公司加速早期研發管線並確保合規性的需求。隨著申辦者對臨床級試劑的需求日益成長，企業對CDMO的依賴性也隨之增加，以降低專業化生產相關的資本投入和技術風險。市場正逐步從利基供應商轉向一體化的全球企業，例如，虛擬生物技術公司利用CDMO加速I期臨床試驗。技術專業化是關鍵的成長要素，因為複雜的治療方法需要外包先進的生產技術。此外，人工智慧正在透過增強數據利用、預測分析和流程最佳化來革新該行業的效率。這將最終加快臨床試劑的供應，並提升小規模生技公司的產能。

全球臨床實驗藥物CDMO市場的促進因素

全球臨床實驗藥物CDMO市場的一個關鍵趨勢是，生物製藥申辦者擴大將複雜的早期研發任務外包給專業的合約研發生產機構（CDMO）。這種轉變源自於申辦方對外部合作夥伴的需求，這些合作夥伴能夠提供全面的能力、先進的技術知識和集中的專案管理，從而使申辦方避免建立和維護內部專業團隊的複雜性和成本。外包使申辦方能夠專注於其核心治療策略和臨床計劃，同時利用CDMO的營運柔軟性和科學專長。因此，對CDMO的持續依賴正在推動對客製化服務、產能擴張以及業內長期商業性合作關係建立的需求成長。

全球臨床實驗藥物CDMO市場的限制因素

由於臨床實驗性藥物監管環境複雜多變，全球臨床實驗藥物合約研發生產機構 (CDMO) 市場面臨嚴峻挑戰。這種複雜性對 CDMO 及其客戶提出了更高的合規要求，使得專案設計、文件編制和品質保證更加困難。為了維持合規，服務供應商必須及時更新監管知識，嚴格執行生產規程，並準備全面的監管申報資料。這增加了營運的複雜性和資源分配的負擔。這種監管負擔可能會阻礙小規模供應商進入臨床實驗服務領域，導致申辦者傾向於選擇擁有良好合規記錄的成熟合作夥伴。反過來，這又限制了競爭，阻礙了市場產能的擴張。

全球臨床實驗新藥（IND）CDMO市場趨勢

全球臨床實驗藥物（IND）合約研發生產力機構（CDMO）市場正經歷重大變革，其驅動力是生物製藥和細胞療法需求的不斷成長。隨著製藥公司和研究機構尋求外部專業知識來應對這些先進治療方法的複雜性，CDMO正在加強其在製程開發、小批量生產和療效維持方面的能力。這項變革涉及對專用平台、一次性系統和強大的低溫運輸物流的大量投資，以滿足個人化醫療和適應性臨床項目的需求。與申辦方在客製化工作流程和技術轉移方面加強合作，提高了CDMO的靈活性，使其能夠快速適應臨床試驗的動態需求，同時始終堅持以患者為中心的理念，並專注於品質。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

Lonza Group
Thermo Fisher Scientific
Catalent Inc.
WuXi AppTec
Samsung Biologics
Boehringer Ingelheim
AGC Biologics
Recipharm AB
Patheon（Thermo Fisher）
Siegfried Holding
Almac Group
Curia Global
Cambrex Corporation
Bachem Holding
PharmaLex

結論與建議

簡介目錄

Product Code: SQMIG35J2277

Global Investigational New Drug Cdmo Market size was valued at USD 4.22 Billion in 2024 and is poised to grow from USD 4.76 Billion in 2025 to USD 12.58 Billion by 2033, growing at a CAGR of 12.84% during the forecast period (2026-2033).

The global Investigational New Drug (IND) Contract Development and Manufacturing Organization (CDMO) market is driven primarily by the need for biopharma companies to expedite their early-stage pipelines while ensuring regulatory compliance. As sponsors seek to produce clinical-grade materials, they increasingly rely on CDMOs to reduce capital expenditure and technical risks associated with specialized manufacturing. The market has gradually shifted from niche providers to integrated global entities, exemplified by virtual biotech firms leveraging CDMOs for rapid Phase I advancements. Key growth factors include technological specialization, as complex modalities necessitate outsourcing advanced manufacturing expertise. Furthermore, AI is revolutionizing efficiency within this space by enhancing data utilization, predictive analytics, and process optimization, ultimately ensuring faster clinical supply and bolstering capacity for small biotech companies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Investigational New Drug Cdmo market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Investigational New Drug Cdmo Market Segments Analysis

Global investigational new drug cdmo market is segmented by service type, drug type, phase, therapeutic area and region. Based on service type, the market is segmented into API Development & Manufacturing, Formulation Development, Analytical & Testing Services, Fill-Finish Services and Others. Based on drug type, the market is segmented into Small Molecule Drugs, Biologics, Oligonucleotides and Others. Based on phase, the market is segmented into Phase I, Phase II and Phase III. Based on therapeutic area, the market is segmented into Oncology, CNS Disorders, Infectious Diseases and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Investigational New Drug Cdmo Market

A significant trend in the Global Investigational New Drug CDMO market is the increasing inclination among biopharmaceutical sponsors to outsource intricate early development tasks to specialized contract development and manufacturing organizations. This shift is driven by the desire for external partners who can offer comprehensive capabilities, advanced technical knowledge, and focused project management, allowing sponsors to avoid the complexities and costs of establishing and maintaining in-house expertise. By outsourcing, sponsors can emphasize their core therapeutic strategies and clinical planning while benefiting from the operational flexibility and scientific proficiency of CDMOs. Consequently, this ongoing reliance on CDMOs fosters a growing demand for customized services, expansion of capacities, and the establishment of long-term commercial collaborations within the industry.

Restraints in the Global Investigational New Drug Cdmo Market

The Global Investigational New Drug Contract Development and Manufacturing Organization (CDMO) market faces significant challenges due to the intricate and shifting regulatory landscape surrounding investigational substances. These complexities create substantial compliance demands on CDMOs and their clients, making project design, documentation, and quality assurance more difficult. To remain compliant, service providers must consistently update their regulatory knowledge, enforce stringent manufacturing protocols, and prepare comprehensive regulatory submissions, which adds to their operational complexity and resource allocation. This regulatory burden may dissuade smaller providers from entering the investigational services space, leading sponsors to prefer established partners with proven compliance records, thus limiting competition and hindering market capacity expansion.

Market Trends of the Global Investigational New Drug Cdmo Market

The Global Investigational New Drug (IND) CDMO market is witnessing a significant shift driven by the increasing demand for biologics and cell therapies. As pharmaceutical companies and research institutions seek outsourced expertise to navigate the complexities of these advanced therapies, CDMOs are enhancing their capabilities in process development, small-batch manufacturing, and potency preservation. This evolution involves substantial investments in specialized platforms, single-use systems, and robust cold-chain logistics to meet the needs of personalized medicine and adaptive clinical programs. Enhanced collaboration with sponsors on customized workflows and technology transfers is fostering greater agility, allowing CDMOs to adapt swiftly to dynamic trial demands while maintaining a steadfast focus on quality and patient-centric approaches.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape

Global Investigational New Drug CDMO Market Size by Service Type & CAGR (2026-2033)

Market Overview
API Development & Manufacturing
Formulation Development
Analytical & Testing Services
Fill-Finish Services
Others

Global Investigational New Drug CDMO Market Size by Drug Type & CAGR (2026-2033)

Market Overview
Small Molecule Drugs
Biologics
Oligonucleotides
Others

Global Investigational New Drug CDMO Market Size by Phase & CAGR (2026-2033)

Market Overview
Phase I
Phase II
Phase III

Global Investigational New Drug CDMO Market Size by Therapeutic Area & CAGR (2026-2033)

Market Overview
Oncology
CNS Disorders
Infectious Diseases
Others

Global Investigational New Drug CDMO Market Size & CAGR (2026-2033)

North America (Service Type, Drug Type, Phase, Therapeutic Area)
- US
- Canada
Europe (Service Type, Drug Type, Phase, Therapeutic Area)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Service Type, Drug Type, Phase, Therapeutic Area)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Service Type, Drug Type, Phase, Therapeutic Area)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Service Type, Drug Type, Phase, Therapeutic Area)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Lonza Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalent Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi AppTec
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Samsung Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AGC Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Recipharm AB
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Patheon (Thermo Fisher)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siegfried Holding
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Almac Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Curia Global
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cambrex Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bachem Holding
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PharmaLex
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments